Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: Detection bias and resolution of discrepant findings in two Women's Health Initiative studies

Climacteric

Volumn 9, Issue 6, 2006, Pages 416-420

  Shapiro, S ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cardiovascular disease; Detection bias; Postmenopausal hormone therapy; Women's Health Initiative

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;

AWARENESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA ANALYSIS; DISEASE ASSOCIATION; EXPOSURE; FOLLOW UP; HEART INFARCTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MASS MEDIUM; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE; SUPPLEMENTATION; TREATMENT DURATION; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

EID: 33750609871     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130601012061     Document Type: Review

References (15)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results in the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
2. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl Med J 2003;349;523-34
3. Meade TW, Vickers MR. HRT and cardiovascular disease. J Epidemiol Biostat 1999;4:165-90
4. Prentice RL, Langer R, Stefanik ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-14
5. Curb D, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication in the Women's Health Initiative. Ann Epidemiol 2003:13(Suppl):S122-8
6. Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: Women's Health Initiative. JAMA 2003;289:2673-84
7. Cushman M, Kuller LH, Prentice RL, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
8. Petitti DB, Freedman DA. Invited commentary; how far can epidemiologists get with statistical adjustment? Am J Epidemiol 2005;162:415-18
9. Prentice RL, Langer R, Anderson G, Barad D. Response to "How far can epidemiologists get with statistical adjustment? Am J Epidemiol 2005;162:419-20
10. Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;5:302-10
11. Shapiro S. Adverse neoplastic and cardiovascular outcomes of HRT. The validity of the evidence. Endocrine 2004;24(Suppl):203-10
12. Garbe E, Suissa S. Issues to debate on the Women's Health Study. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod 2004;19:8-13
13. Chlebowski RT, Hendrix SI, Langer RD, et al. Influence of estrogen plus progestin on breast cancer mamography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289;3243-53
14. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
15. Castellsague J, Perez Gutthann S, Garcia Rodriguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Pharmacoepidemiology 1998;18:117-23